» Articles » PMID: 32887946

Gut Microbiota in Human Metabolic Health and Disease

Overview
Date 2020 Sep 5
PMID 32887946
Citations 1524
Authors
Affiliations
Soon will be listed here.
Abstract

Observational findings achieved during the past two decades suggest that the intestinal microbiota may contribute to the metabolic health of the human host and, when aberrant, to the pathogenesis of various common metabolic disorders including obesity, type 2 diabetes, non-alcoholic liver disease, cardio-metabolic diseases and malnutrition. However, to gain a mechanistic understanding of how the gut microbiota affects host metabolism, research is moving from descriptive microbiota census analyses to cause-and-effect studies. Joint analyses of high-throughput human multi-omics data, including metagenomics and metabolomics data, together with measures of host physiology and mechanistic experiments in humans, animals and cells hold potential as initial steps in the identification of potential molecular mechanisms behind reported associations. In this Review, we discuss the current knowledge on how gut microbiota and derived microbial compounds may link to metabolism of the healthy host or to the pathogenesis of common metabolic diseases. We highlight examples of microbiota-targeted interventions aiming to optimize metabolic health, and we provide perspectives for future basic and translational investigations within the nascent and promising research field.

Citing Articles

Causal associations between 26 musculoskeletal disorders and gut microbiota: a Mendelian randomization analysis with Bayesian validation.

Wang Y, Sun Y, Liao H World J Microbiol Biotechnol. 2025; 41(3):106.

PMID: 40080232 PMC: 11906543. DOI: 10.1007/s11274-025-04318-6.


Evaluation of gut microbiota alterations following orlistat administration in obese mice.

Xue C, Wang T, Chen Y, Zhang H, Wang H, Li Q Front Endocrinol (Lausanne). 2025; 15:1337245.

PMID: 40078888 PMC: 11896870. DOI: 10.3389/fendo.2024.1337245.


Gut microbiota therapy in gastrointestinal diseases.

Ullah H, Arbab S, Chang C, Bibi S, Muhammad N, Rehman S Front Cell Dev Biol. 2025; 13:1514636.

PMID: 40078367 PMC: 11897527. DOI: 10.3389/fcell.2025.1514636.


Milk Exosome-Based Delivery System for Probiotic Encapsulation That Enhances the Gastrointestinal Resistance and Adhesion of Probiotics.

Hao L, Liu Y, Szeto I, Hao H, Zhang T, Liu T Nutrients. 2025; 17(5).

PMID: 40077793 PMC: 11902061. DOI: 10.3390/nu17050923.


Unlocking the Microbial Symphony: The Interplay of Human Microbiota in Cancer Immunotherapy Response.

Chacon J, Faizuddin F, McKee J, Sheikh A, Vasquez Jr V, Gadad S Cancers (Basel). 2025; 17(5).

PMID: 40075661 PMC: 11899421. DOI: 10.3390/cancers17050813.


References
1.
Lynch S, Pedersen O . The Human Intestinal Microbiome in Health and Disease. N Engl J Med. 2016; 375(24):2369-2379. DOI: 10.1056/NEJMra1600266. View

2.
Jaacks L, Vandevijvere S, Pan A, McGowan C, Wallace C, Imamura F . The obesity transition: stages of the global epidemic. Lancet Diabetes Endocrinol. 2019; 7(3):231-240. PMC: 7360432. DOI: 10.1016/S2213-8587(19)30026-9. View

3.
Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

4.
Zheng Y, Ley S, Hu F . Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2017; 14(2):88-98. DOI: 10.1038/nrendo.2017.151. View

5.
Reddy K, Yusuf S . Emerging epidemic of cardiovascular disease in developing countries. Circulation. 1998; 97(6):596-601. DOI: 10.1161/01.cir.97.6.596. View